DCF Advisers LLC Sells 5,600 Shares of Eli Lilly and Company $LLY

Key Points

• DCF Advisers LLC cut its Eli Lilly stake by 67.5% in the second quarter, selling 5,600 shares and retaining 2,700 shares valued at approximately $3.24 million. Institutional investors collectively own 82.53% of LLY.
• Eli Lilly reported strong quarterly results, with revenue rising 47.7% year over year to $22.97 billion and EPS of $8.38, well above analysts’ $6.40 estimate. The company maintained 2026 EPS guidance of $35.50–$36.50.
• Despite positive developments including FDA clearance for an Alzheimer’s blood test and the U.K. launch of its oral weight-loss drug, LLY remains sensitive to valuation and profit-taking after a major rally. Shares were down 0.6%, while analysts maintained an overall “Moderate Buy” rating with an average target of $1,292.18.

DCF Advisers LLC decreased its stake in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 67.5% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 2,700 shares of the company's stock after selling 5,600 shares during the quarter. DCF Advisers LLC's holdings in Eli Lilly and Company were worth $3,238,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in LLY. Willner & Heller LLC lifted its holdings in shares of Eli Lilly and Company by 1.0% during the second quarter. Willner & Heller LLC now owns 917 shares of the company's stock valued at $1,100,000 after purchasing an additional 9 shares in the last quarter. Aspiring Ventures LLC grew its position in Eli Lilly and Company by 3.7% during the second quarter. Aspiring Ventures LLC now owns 255 shares of the company's stock valued at $306,000 after buying an additional 9 shares during the period. Wealthspan Partners LLC raised its holdings in Eli Lilly and Company by 0.4% in the 2nd quarter. Wealthspan Partners LLC now owns 2,120 shares of the company's stock worth $2,543,000 after purchasing an additional 9 shares during the period. Navigoe LLC raised its stake in shares of Eli Lilly and Company by 8.7% in the second quarter. Navigoe LLC now owns 113 shares of the company's stock worth $135,000 after buying an additional 9 shares during the period. Finally, Serenus Wealth Advisors LLC raised its stake in Eli Lilly and Company by 2.3% during the 4th quarter. Serenus Wealth Advisors LLC now owns 439 shares of the company's stock worth $472,000 after acquiring an additional 10 shares during the period. 82.53% of the stock is owned by institutional investors.

Key Headlines Impacting Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: The FDA cleared an Alzheimer’s blood test developed by Roche and Eli Lilly to help identify signs of the disease in people aged 55 and older who have cognitive decline. The approval expands Lilly’s potential presence in Alzheimer’s diagnostics and supports its broader neuroscience strategy. Roche, Eli Lilly's Alzheimer's blood test gets FDA clearance
• Positive Sentiment: Lilly launched its once-daily oral weight-loss and diabetes treatment Foundayo, or orforglipron, in U.K. pharmacies. The European rollout gives patients an alternative to injectable GLP-1 drugs and provides a new commercial growth opportunity in the expanding obesity-treatment market. Eli Lilly launches oral weight-loss pill Foundayo in UK
• Positive Sentiment: Citadel, led by Ken Griffin, reportedly nearly quadrupled its Eli Lilly position in the second quarter, building a stake valued at approximately $1.1 billion. The move may reinforce investor confidence in Lilly’s diabetes, obesity and pipeline growth prospects. Eli Lilly Stock in Focus as Hedge Fund Titan Ken Griffin Quadruples Position
• Neutral Sentiment: Analysts and investor commentary continue to highlight the possibility of $100 billion-plus annual revenue, supported by GLP-1 demand and upcoming pipeline catalysts. However, those expectations are already reflected in Lilly’s roughly $1.17 trillion market capitalization, raising the bar for further gains.
• Negative Sentiment: Healthcare stocks broadly weakened during afternoon trading, creating sector-wide pressure on Lilly independent of company-specific developments. Sector Update: Healthcare Stocks Decline in Afternoon Trading
• Negative Sentiment: Lilly’s retreat also reflects profit-taking and valuation sensitivity after a major rally. Investors may be questioning whether extraordinary growth in obesity drugs can continue to justify the company’s elevated valuation amid intensifying competition from Novo Nordisk and other emerging treatments. Eli Lilly Slips as Its Valuation Cools

Eli Lilly and Company Stock Down 0.6%

Shares of LLY opened at $1,247.92 on Tuesday. Eli Lilly and Company has a 12-month low of $694.23 and a 12-month high of $1,292.65. The firm has a fifty day moving average price of $1,182.50 and a 200-day moving average price of $1,061.66. The firm has a market capitalization of $1.17 trillion, a P/E ratio of 41.88, a P/E/G ratio of 1.48 and a beta of 0.51. The company has a current ratio of 1.35, a quick ratio of 1.00 and a debt-to-equity ratio of 1.41.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last released its quarterly earnings data on Wednesday, August 5th. The company reported $8.38 earnings per share (EPS) for the quarter, beating the consensus estimate of $6.40 by $1.98. Eli Lilly and Company had a net margin of 33.53% and a return on equity of 97.83%. The company had revenue of $22.97 billion during the quarter, compared to analysts' expectations of $20.82 billion. During the same period in the previous year, the company earned $6.31 EPS. The firm's quarterly revenue was up 47.7% on a year-over-year basis. Eli Lilly and Company has set its FY 2026 guidance at 35.500-36.500 EPS. Equities research analysts expect that Eli Lilly and Company will post 36.35 earnings per share for the current year.

Eli Lilly and Company Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Thursday, September 10th. Shareholders of record on Friday, August 14th will be given a dividend of $1.73 per share. The ex-dividend date of this dividend is Friday, August 14th. This represents a $6.92 dividend on an annualized basis and a yield of 0.6%. Eli Lilly and Company's payout ratio is 23.22%.

Analyst Ratings Changes

LLY has been the topic of several recent analyst reports. Wall Street Zen downgraded shares of Eli Lilly and Company from a "strong-buy" rating to a "buy" rating in a research report on Sunday. JPMorgan Chase & Co. increased their price objective on shares of Eli Lilly and Company from $1,300.00 to $1,400.00 and gave the company an "overweight" rating in a report on Tuesday, July 7th. The Goldman Sachs Group restated a "buy" rating and issued a $1,283.00 price target on shares of Eli Lilly and Company in a research report on Friday, May 22nd. Rothschild & Co Redburn boosted their target price on Eli Lilly and Company from $880.00 to $900.00 in a research report on Thursday, May 7th. Finally, Guggenheim raised their target price on shares of Eli Lilly and Company from $1,235.00 to $1,273.00 and gave the stock a "buy" rating in a report on Monday, July 13th. One analyst has rated the stock with a Strong Buy rating, twenty-four have assigned a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average target price of $1,292.18.

Insiders Place Their Bets

In other news, EVP Patrik Jonsson sold 6,500 shares of the stock in a transaction on Monday, August 17th. The stock was sold at an average price of $1,175.10, for a total transaction of $7,638,150.00. Following the transaction, the executive vice president owned 54,147 shares of the company's stock, valued at approximately $63,628,139.70. This represents a 10.72% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Anat Hakim sold 5,000 shares of the firm's stock in a transaction on Friday, August 7th. The shares were sold at an average price of $1,190.00, for a total value of $5,950,000.00. Following the transaction, the executive vice president owned 11,875 shares in the company, valued at approximately $14,131,250. This represents a 29.63% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 13,500 shares of company stock worth $15,958,170. 0.14% of the stock is currently owned by company insiders.

Eli Lilly and Company Company Profile

Eli Lilly and Company NYSE: LLY is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source